Assembly Biosciences (NASDAQ:ASMB) Sees Large Volume Increase – Should You Buy?

Assembly Biosciences, Inc. (NASDAQ:ASMB) shares saw unusually-strong trading volume on Wednesday . 364,071 shares changed hands during trading, an increase of 121% from the previous session’s volume of 164,453 shares.The stock last traded at $33.89 and had previously closed at $35.28.

Assembly Biosciences News Roundup

Here are the key news stories impacting Assembly Biosciences this week:

• Positive Sentiment: HC Wainwright raised its $50 price target and maintained a Buy rating. The firm increased its FY2027 EPS forecast from a loss of $0.02 to $0.05 and lifted estimates for 2027 quarterly earnings, FY2028 EPS to $0.84 from $0.80, and FY2030 EPS to $3.32 from $3.28. The higher long-term estimates imply substantial upside if Assembly’s pipeline and commercialization plans progress as expected. HC Wainwright analyst estimate updates
• Positive Sentiment: Management will present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference on September 16. Investors may look for updates on Assembly’s development programs targeting serious viral and liver diseases, creating a potential near-term catalyst. Assembly Biosciences conference presentation announcement
• Neutral Sentiment: Reported short interest was zero shares. This indicates no measurable short-selling pressure in the supplied data, although the reported increase is not meaningful because both periods showed zero shares and the figures appear incomplete.
• Neutral Sentiment: Assembly was included by Zacks among defensive stock ideas amid oil-price and geopolitical volatility. However, the designation is market-themed rather than a company-specific business or pipeline catalyst. Zacks defensive stock picks article
• Negative Sentiment: Although estimates improved, HC Wainwright still projects losses of $0.83 and $0.84 per share in the second and third quarters of 2027 and a $2.22 loss for FY2029. Those forecasts highlight ongoing execution and funding risks, which may be weighing on the stock despite the favorable long-term outlook.

Wall Street Analysts Forecast Growth

ASMB has been the subject of a number of research analyst reports. Wall Street Zen cut shares of Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 16th. Mizuho set a $53.00 target price on shares of Assembly Biosciences in a research note on Tuesday, September 1st. HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Assembly Biosciences in a report on Tuesday, August 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Friday, July 17th. Finally, Zacks Research raised shares of Assembly Biosciences from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 20th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $45.60.

Assembly Biosciences Stock Performance

The stock has a market capitalization of $620.17 million, a price-to-earnings ratio of 29.86 and a beta of 1.13. The business has a fifty day simple moving average of $29.73 and a 200 day simple moving average of $28.38.

Assembly Biosciences (NASDAQ:ASMB) last announced its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.52. Assembly Biosciences had a negative net margin of 0.06% and a negative return on equity of 0.02%. The company had revenue of $13.37 million during the quarter, compared to analysts’ expectations of $8.60 million. On average, sell-side analysts forecast that Assembly Biosciences, Inc. will post 2.28 earnings per share for the current fiscal year.

Institutional Trading of Assembly Biosciences

A number of institutional investors have recently modified their holdings of ASMB. Seven Fleet Capital Management LP raised its position in shares of Assembly Biosciences by 671.5% in the 2nd quarter. Seven Fleet Capital Management LP now owns 433,147 shares of the biopharmaceutical company’s stock valued at $11,903,000 after buying an additional 377,000 shares in the last quarter. Stempoint Capital LP lifted its holdings in shares of Assembly Biosciences by 18.3% during the 1st quarter. Stempoint Capital LP now owns 185,435 shares of the biopharmaceutical company’s stock worth $5,146,000 after acquiring an additional 28,707 shares during the period. Eversept Partners LP acquired a new stake in shares of Assembly Biosciences during the 4th quarter worth approximately $5,431,000. 683 Capital Management LLC bought a new position in Assembly Biosciences in the fourth quarter valued at approximately $948,000. Finally, Squarepoint Ops LLC increased its stake in Assembly Biosciences by 43.7% in the second quarter. Squarepoint Ops LLC now owns 34,214 shares of the biopharmaceutical company’s stock valued at $940,000 after acquiring an additional 10,410 shares during the last quarter. 19.92% of the stock is currently owned by institutional investors.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.